TOP 1902 (Non-Small Cell Lung Cancer)

What is the Purpose of this Study?

If you choose to join this study, you will:
- Have a physical exam
- Have blood samples taken
- Get the study drug (GT-103) every 3 weeks as long as you continue to do well and tolerate the drug. The study drug will be given into your arm by an IV.

Once you complete your treatment, you will complete a follow-up phone call every 12 weeks for up to 3 years.
What is the Condition Being Studied?
Advanced Stage Non-Small Cell Lung Cancer

Who Can Participate in this Study?

Adults 18+ who:

- Have a diagnosis of advanced non-small cell lung cancer

For more information about who can join this study, please contact the study team at 919-681-4768.

Age Group
Adults
Participating Institutions
Duke University Health System
Karmanos Cancer Institute
AdventHealth

What is Involved?

We are doing this study to learn more about the study drug (GT-103) and to find the best dose to give to patients with advanced NSCLC.

Study Details

Full Title
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
Principal Investigator

Contacts
Protocol Number
IRB:
PRO00104564

NCT:
NCT04314089
ClinicalTrials.gov
View on ClinicalTrials.gov